Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming UBS 2025 Virtual Oncology Day.

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming UBS 2025 Virtual Oncology Day. The company's CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in a fireside chat on October 1, 2025, at 3:30 p.m. ET.

Investors can access the live webcast through Nuvalent's website investor section, where it will remain available for 30 days after the presentation.

Argus Sep 24 session

-1.90% close to close Open Argus

Details

News Market Reaction – NUVL

On Sep 24, the day this news came out, NUVL closed 1.90% below the previous close.

Data tracked by StockTitan Argus for the Sep 24 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the UBS 2025 Virtual Oncology Day on Wednesday, October 1, 2025, at 3:30 p.m. ET.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-ubs-2025-virtual-oncology-day-302565104.html

SOURCE Nuvalent, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Nuvalent (NUVL) presenting at the UBS 2025 Virtual Oncology Day?

Nuvalent will present on Wednesday, October 1, 2025, at 3:30 p.m. ET through a fireside chat.

Who will represent Nuvalent at the UBS 2025 Virtual Oncology Day?

James Porter, Ph.D. (Chief Executive Officer) and Alexandra Balcom (Chief Financial Officer) will represent Nuvalent.

How can investors access Nuvalent's UBS Oncology Day presentation?

Investors can access the live webcast through the Investors section of Nuvalent's website (www.nuvalent.com). The presentation will be archived for 30 days afterward.

What type of company is Nuvalent (NUVL)?

Nuvalent is a clinical-stage biopharmaceutical company that focuses on developing precisely targeted therapies for clinically proven kinase targets in cancer.